Seelos Therapeutics, Inc has filed a notice of a Private Investment in Public Equity (PIPE) offering of securities to raise $4,000,000.00 in New Funding.
According to filings with the U.S. Securities and Exchange Commission, Seelos Therapeutics, Inc. is raising $4,000,000.00 in new funding. About Seelos Therapeutics, Inc.: Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company’s lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson’s disease (PD). Its preclinical programs include SLS-007, a peptidic inhibitor to treat patients with PD; SLS-008 for the treatment of pediatric indications; SLS-004 for the treatment of PD; SLS-010, an H3 receptor antagonist; and SLS-012. The company was founded in 2016 and is headquartered in New York, New York.
To learn more about Seelos Therapeutics, Inc., visit http://www.seelostherapeutics.com/
Contact:
Raj Mehra, President and Chief Executive Officer
646-293-2100
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.